Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Co-Treatment With Vitamin C Increases Therapeutic Effect of Chemotherapy in Cisplatin-Ineligible MIBC

May 15th 2022

Cisplatin-ineligible patients with locally advanced muscle invasive bladder cancer undergoing chemotherapy may benefit from simultaneous treatment with intravenous vitamin C.

Dr. Galsky on Updated CheckMate 274 Data With Adjuvant Nivolumab in Urothelial Carcinoma

May 15th 2022

Matthew Galsky, MD, discusses long-term data from the phase 3 CheckMate 274 trial evaluating adjuvant nivolumab vs placebo in patients with high-risk, muscle-invasive urothelial cancer.

Up-Front Avelumab Maintenance Improves OS in Urothelial Carcinoma

May 14th 2022

Avelumab plus best supportive care produced a benefit in overall survival in patients with advanced urothelial carcinoma that had not progressed with first-line platinum-based chemotherapy.

Dr. Khetrapal on Intracorporeal Robotic vs Open Cystectomy in MIBC

May 14th 2022

Pramit Khetrapal, MD, discusses the results of evaluating intracorporeal robotic vs open cystectomy in a multicenter, randomized trial in patients with muscle-invasive bladder cancer.

Nivolumab Offers Long-Term DFS Benefits in Urothelial Carcinoma

May 14th 2022

According to longer follow-up data from the phase 3 CheckMate 274 trial, patients with high-risk, muscle-invasive urothelial carcinoma continued to experience clinically meaningful improvements in disease-free survival when treated with adjuvant nivolumab vs placebo.

N-803 Plus BCG Produces Clinically Meaningful Benefit in BCG-Unresponsive Bladder Cancer

May 13th 2022

The addition of the IL15RaFc superagonist N-803 to Bacillus Calmette–Guérin led to prolonged complete responses and disease-free survival (DFS) in patients with BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ and papillary histology, respectively.

Immune-Related Adverse Effects Linked to Longer Survival With Pembrolizumab in Metastatic Urothelial Carcinoma

May 13th 2022

Patients with metastatic urothelial carcinoma who received pembrolizumab achieved prolonged median progression-free and overall survival after experiencing an immune-related adverse effect.

Pembrolizumab Plus Chemoradiotherapy to Be Investigated as Bladder-Preservation Treatment in MIBC

May 10th 2022

Pembrolizumab plus concurrent chemoradiotherapy is being investigated as a potential therapy in patients with muscle-invasive bladder cancer.

CG0070 Plus Nivolumab Under Investigation in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

May 4th 2022

The safety and efficacy of the combination of the oncolytic immunotherapy CG0070 and nivolumab is under exploration as a potential therapeutic option in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy, as part of the phase 1b CORE-002 trial.

Dr. Grivas on the TROPHY U-01 Trial in Urothelial Cancer

May 2nd 2022

Petros Grivas, MD, PhD, discusses the phase 2 TROPHY U-01 trial in metastatic urothelial cancer.

Dr. Iacovelli on Key Takeaways from the ARIES Trial in Urothelial Cancer

May 2nd 2022

Roberto Iacovelli, MD, PhD, discusses the key takeaways of the phase 2 ARIES trial in urothelial cancer.

Dr. Munver on the Approval of Mitomycin Gel in Urothelial Cancer

April 29th 2022

Ravi Munver, MD, discusses the approval of mitomycin gel in urothelial cancer.

Institutional Perspectives in Cancer- Bladder/RCC: Chaired by Mark T. Fleming, MD

April 26th 2022

Institutional Perspectives in Cancer- Bladder/RCC: Chaired by Mark T. Fleming, MD

Immune Checkpoint Inhibitors, Expanding Trials Signal Progress in Advanced Urothelial Carcinoma

April 22nd 2022

Matthew Galsky, MD, discusses the impact of recent developments in the advanced urothelial carcinoma treatment paradigm.

Trimodality Approach to MIBC Paves Path for Bladder Preservation

April 20th 2022

Standard chemoradiation therapy regimens have had marked success for patients with muscle-invasive bladder cancer; however, up to 30% of patients who receive treatment with bladder preserving intent will have recurrence.

Enfortumab Vedotin Approved in Europe for Locally Advanced or Metastatic Urothelial Cancer

April 13th 2022

The European Commission has approved enfortumab vedotin for use as a single agent in adult patients with locally advanced or metastatic urothelial cancer who have received prior platinum-containing therapy and a PD-1/L1 inhibitor.

Dr. Ornstein on the Benefit of Neoadjuvant Therapy in RCC

April 13th 2022

Moshe Ornstein, MD, MA, discusses the benefit of neoadjuvant therapy in renal cell carcinoma.

Dr. Iacovelli on Eligibility Criteria of the ARIES Trial in Urothelial Cancer

April 13th 2022

Roberto Iacovelli, MD, PhD, discusses the patient eligibility criteria of the phase 2 ARIES trial in urothelial cancer.

Pembrolizumab Plus CG0070 Induces Promising Response Rates in BCG-Unresponsive NMIBC

April 13th 2022

The addition of the selective oncolytic adenovirus CG0070 to pembrolizumab showed encouraging activity and safety in Bacillus Calmette-Guerin–unresponsive non-muscle invasive bladder cancer, according to early data from the phase 2 CORE1 trial.

NICE Makes Avelumab Available for Maintenance Treatment of Urothelial Cancer

April 8th 2022

Avelumab is now a treatment option for patients with urothelial cancer in the United Kingdom following a recommendation from the National Institute for Health and Care Excellence issued Thursday, April 7, 2022.1